NO313405B1 - Sammensetning inneholdende minst ett glukokortikoid i kombinasjon med et pulmonart overflateaktivt middel til behandling av IRDS og ARDS - Google Patents
Sammensetning inneholdende minst ett glukokortikoid i kombinasjon med et pulmonart overflateaktivt middel til behandling av IRDS og ARDS Download PDFInfo
- Publication number
- NO313405B1 NO313405B1 NO19971403A NO971403A NO313405B1 NO 313405 B1 NO313405 B1 NO 313405B1 NO 19971403 A NO19971403 A NO 19971403A NO 971403 A NO971403 A NO 971403A NO 313405 B1 NO313405 B1 NO 313405B1
- Authority
- NO
- Norway
- Prior art keywords
- ards
- treatment
- irds
- composition
- surfactant
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 title claims abstract description 20
- 239000003580 lung surfactant Substances 0.000 title claims abstract description 16
- 201000000028 adult respiratory distress syndrome Diseases 0.000 title claims abstract description 15
- 239000003862 glucocorticoid Substances 0.000 title claims abstract description 8
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 14
- 210000004072 lung Anatomy 0.000 claims description 7
- 229940066294 lung surfactant Drugs 0.000 claims description 7
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 102000000528 Pulmonary Surfactant-Associated Proteins Human genes 0.000 claims description 5
- 108010041520 Pulmonary Surfactant-Associated Proteins Proteins 0.000 claims description 5
- 229960002537 betamethasone Drugs 0.000 claims description 5
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 5
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 claims description 4
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 claims description 4
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims description 3
- 229960003728 ciclesonide Drugs 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 claims description 2
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229960001810 meprednisone Drugs 0.000 claims 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 abstract description 2
- 244000144985 peep Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 5
- 230000009467 reduction Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229940063649 survanta Drugs 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940092456 curosurf Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4434629A DE4434629C1 (de) | 1994-09-28 | 1994-09-28 | Zusammensetzungen zur Behandlung von IRDS und ARDS |
| PCT/EP1995/003816 WO1996009831A2 (de) | 1994-09-28 | 1995-09-27 | Zusammensetzungen zur behandlung von irds und ards, die mindestens ein glucocorticosteroid in kombination mit einem lungen surfactant enthalten |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO971403D0 NO971403D0 (no) | 1997-03-25 |
| NO971403L NO971403L (no) | 1997-04-17 |
| NO313405B1 true NO313405B1 (no) | 2002-09-30 |
Family
ID=6529394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19971403A NO313405B1 (no) | 1994-09-28 | 1997-03-25 | Sammensetning inneholdende minst ett glukokortikoid i kombinasjon med et pulmonart overflateaktivt middel til behandling av IRDS og ARDS |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US5891844A (sv) |
| EP (1) | EP0783314B1 (sv) |
| JP (1) | JP4425991B2 (sv) |
| KR (1) | KR100365030B1 (sv) |
| CN (1) | CN1100542C (sv) |
| AT (1) | ATE241372T1 (sv) |
| AU (1) | AU705099B2 (sv) |
| BG (1) | BG62556B1 (sv) |
| CA (1) | CA2201377C (sv) |
| CZ (1) | CZ292846B6 (sv) |
| DE (2) | DE4434629C1 (sv) |
| DK (1) | DK0783314T3 (sv) |
| EE (1) | EE03422B1 (sv) |
| ES (1) | ES2201120T3 (sv) |
| FI (1) | FI118886B (sv) |
| HK (1) | HK1003869A1 (sv) |
| HU (1) | HU226958B1 (sv) |
| MX (1) | MX9702303A (sv) |
| NO (1) | NO313405B1 (sv) |
| NZ (1) | NZ294587A (sv) |
| PL (1) | PL187496B1 (sv) |
| PT (1) | PT783314E (sv) |
| RU (1) | RU2157222C2 (sv) |
| SK (1) | SK284446B6 (sv) |
| UA (1) | UA43378C2 (sv) |
| WO (1) | WO1996009831A2 (sv) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6039932A (en) * | 1996-09-27 | 2000-03-21 | 3M Innovative Properties Company | Medicinal inhalation aerosol formulations containing budesonide |
| CA2276429C (en) * | 1997-02-17 | 2007-06-19 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Compositions for the treatment of ards or irds containing 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide and lung surfactant |
| US7122344B2 (en) | 1997-05-28 | 2006-10-17 | Claragen, Inc. | Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| US20060281681A1 (en) | 1997-05-28 | 2006-12-14 | Pilon Aprile L | Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease |
| US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US20020017295A1 (en) * | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
| US6946117B1 (en) * | 1997-09-29 | 2005-09-20 | Nektar Therapeutics | Stabilized preparations for use in nebulizers |
| US6433040B1 (en) * | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
| US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| CN1194833A (zh) * | 1997-10-08 | 1998-10-07 | 刘柏宏 | 肺活素 |
| US6858223B2 (en) | 1998-06-23 | 2005-02-22 | Altana Pharma Ag | Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS) |
| AU5400000A (en) * | 1999-06-11 | 2001-01-02 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c) |
| EP1216052A1 (en) * | 1999-09-16 | 2002-06-26 | Byk Gulden Lomberg Chemische Fabrik GmbH | Combination of c1-inh and lung surfactant for the treatment of respiratory disorders |
| DE19957898A1 (de) * | 1999-12-01 | 2001-06-07 | Byk Gulden Lomberg Chem Fab | Neue Verwendung von Lungensurfactant |
| DE10018022A1 (de) * | 2000-04-12 | 2001-10-31 | Byk Gulden Lomberg Chem Fab | Neue Verwendung von Lungensurfactant zur Prophylaxe oder Frühbehandlung von akuten Lungenerkrankungen |
| CA2405811C (en) * | 2000-04-12 | 2011-09-27 | Altana Pharma Ag | Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases |
| US20040254112A1 (en) * | 2000-04-12 | 2004-12-16 | Dietrich Hafner | Use of pulmonary surfactant for the early treatment of acute pulmonary diseases |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
| TWI290473B (en) * | 2000-05-10 | 2007-12-01 | Alliance Pharma | Phospholipid-based powders for drug delivery |
| DE10132307A1 (de) * | 2001-07-06 | 2003-01-30 | Aventis Behring Gmbh | Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS |
| US20030099601A1 (en) * | 2001-11-27 | 2003-05-29 | Gordon Marc S. | Inhalation lung surfactant therapy |
| US6998384B2 (en) * | 2001-12-12 | 2006-02-14 | The Penn State Research Foundation | Surfactant prevention of lung complications from cancer chemotherapy |
| ATE508735T1 (de) | 2001-12-19 | 2011-05-15 | Novartis Ag | Pulmonale verabreichung von aminoglykosiden |
| US20040023935A1 (en) * | 2002-08-02 | 2004-02-05 | Dey, L.P. | Inhalation compositions, methods of use thereof, and process for preparation of same |
| US20040109826A1 (en) * | 2002-12-06 | 2004-06-10 | Dey, L.P. | Stabilized albuterol compositions and method of preparation thereof |
| CA2529007C (en) | 2003-06-16 | 2012-03-27 | Altana Pharma Ag | Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases |
| PL1670482T5 (pl) * | 2003-09-16 | 2022-10-03 | Covis Pharma Gmbh | Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego |
| US7464012B2 (en) * | 2004-12-10 | 2008-12-09 | L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude | Simplified process simulator |
| US7582312B2 (en) * | 2004-11-15 | 2009-09-01 | Discovery Laboratories, Inc. | Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof |
| PT1841458E (pt) | 2005-01-06 | 2012-04-10 | Discovery Lab Inc | Regime de tratamento com surfactante para tratar ou prevenir displasia broncopulmonar |
| KR100891595B1 (ko) | 2005-02-28 | 2009-04-03 | 주식회사 케이티앤지 | 혈액 단백질의 삼출을 감소시키는 조성물 |
| AU2007297691B2 (en) * | 2006-09-19 | 2013-12-19 | Discovery Laboratories, Inc. | Pulmonary surfactant formulations and methods for promoting mucus clearance |
| EP2022798A1 (en) * | 2007-08-09 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | Synthetic pulmonary surfactant peptides |
| US9345716B2 (en) * | 2010-12-10 | 2016-05-24 | Indian Institute Of Technology, Bombay | Protein free surfactant composition for pulmonary diseases and a process for preparing the same |
| WO2013188016A2 (en) | 2012-05-04 | 2013-12-19 | Discovery Laboratories, Inc. | Surfactant therapy for exposure to ionizing radiation |
| CN106310280A (zh) * | 2016-08-18 | 2017-01-11 | 滨州医学院 | 地瑞那韦增强糖皮质激素抗炎作用的医药新用途 |
| BR112019012922A2 (pt) * | 2016-12-22 | 2019-12-10 | Chiesi Farm Spa | combinação de um surfactante pulmonar, uso de uma combinação de um surfactante pulmonar e kit |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4944941A (en) * | 1987-08-07 | 1990-07-31 | Genentech, Inc. | Methods and compositions for the treatment of lung conditions |
| US5006343A (en) * | 1988-12-29 | 1991-04-09 | Benson Bradley J | Pulmonary administration of pharmaceutically active substances |
-
1994
- 1994-09-28 DE DE4434629A patent/DE4434629C1/de not_active Expired - Lifetime
-
1995
- 1995-09-27 CA CA002201377A patent/CA2201377C/en not_active Expired - Fee Related
- 1995-09-27 RU RU97106790/14A patent/RU2157222C2/ru not_active IP Right Cessation
- 1995-09-27 AU AU37428/95A patent/AU705099B2/en not_active Ceased
- 1995-09-27 KR KR1019970701971A patent/KR100365030B1/ko not_active IP Right Cessation
- 1995-09-27 ES ES95935387T patent/ES2201120T3/es not_active Expired - Lifetime
- 1995-09-27 EE EE9700084A patent/EE03422B1/xx unknown
- 1995-09-27 DK DK95935387T patent/DK0783314T3/da active
- 1995-09-27 SK SK401-97A patent/SK284446B6/sk not_active IP Right Cessation
- 1995-09-27 WO PCT/EP1995/003816 patent/WO1996009831A2/de active IP Right Grant
- 1995-09-27 UA UA97042034A patent/UA43378C2/uk unknown
- 1995-09-27 EP EP95935387A patent/EP0783314B1/de not_active Expired - Lifetime
- 1995-09-27 MX MX9702303A patent/MX9702303A/es unknown
- 1995-09-27 PT PT95935387T patent/PT783314E/pt unknown
- 1995-09-27 CN CN95196265A patent/CN1100542C/zh not_active Expired - Fee Related
- 1995-09-27 JP JP51137796A patent/JP4425991B2/ja not_active Expired - Fee Related
- 1995-09-27 NZ NZ294587A patent/NZ294587A/en not_active IP Right Cessation
- 1995-09-27 HU HU9801664A patent/HU226958B1/hu not_active IP Right Cessation
- 1995-09-27 DE DE59510705T patent/DE59510705D1/de not_active Expired - Lifetime
- 1995-09-27 PL PL95319608A patent/PL187496B1/pl not_active IP Right Cessation
- 1995-09-27 AT AT95935387T patent/ATE241372T1/de active
- 1995-09-27 CZ CZ1997940A patent/CZ292846B6/cs not_active IP Right Cessation
-
1997
- 1997-03-25 NO NO19971403A patent/NO313405B1/no not_active IP Right Cessation
- 1997-03-26 FI FI971277A patent/FI118886B/sv not_active IP Right Cessation
- 1997-04-25 BG BG101441A patent/BG62556B1/bg unknown
- 1997-06-19 US US08/809,687 patent/US5891844A/en not_active Expired - Lifetime
-
1998
- 1998-04-15 HK HK98103100A patent/HK1003869A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO313405B1 (no) | Sammensetning inneholdende minst ett glukokortikoid i kombinasjon med et pulmonart overflateaktivt middel til behandling av IRDS og ARDS | |
| MXPA97002303A (en) | Compositions containing at least one glucocorticoid in combination with a pulmonary surgical agent for the treatment of child respiratory suffering syndrome and respiratory suffering syndrome ag | |
| JP5666569B2 (ja) | サーファクタントタンパク質ｂ（ｓｐ−ｂ）およびサーファクタントタンパク質ｃ（ｓｐ−ｃ）の類似体を含有する改善された再構築サーファクタント組成物 | |
| JP2023113852A (ja) | 進行性のｂｐｄの処置のための肺サーファクタント及びステロイドを含む処置的組み合わせ物 | |
| KR20150089006A (ko) | 재구성된 폐 계면활성제 | |
| EP1216052A1 (en) | Combination of c1-inh and lung surfactant for the treatment of respiratory disorders | |
| JP2934023B2 (ja) | コルチコステロイド治療組成物 | |
| DE69928279T2 (de) | Lungensurfactant zubereitungen enthaltendes behandlungset | |
| EP1480667B1 (en) | Compositions comprising pulmonary surfactants and a polymyxin having improved surface properties | |
| EP1435994B1 (de) | Neue verwendung von lungensurfactant | |
| Spragg et al. | Surfactant Replacement in Patients with Ards: Results of Clinical Trials | |
| Golembeski et al. | New strategies for prevention of neonatal respiratory distress syndrome: Acceleration of fetal lung maturation and exogenous surfactant replacement | |
| Erçin et al. | New Generation Surfactants, Are They A Hope For Better Outcomes? | |
| CREVELD et al. | Modern Aspects of the Treatment of Hemophilia. II. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: TAKEDA GMBH, DE |
|
| MM1K | Lapsed by not paying the annual fees |